Drug Trial Radar · NCT05817240
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
May 3, 2023
Primary completion
Jun 11, 2023
Study completion Jun 21, 2023
Sponsor
- Lead sponsor
- Endeavor Biomedicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
taladegibDrug
100 mg per tablet, dosed once daily
nintedanibDrug
100 mg per capsule, dosed once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nintedanib maximum blood concentration (Cmax) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
- Time of nintedanib maximum blood concentration (Tmax) after coadministration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
- Nintedanib absorption to time t (AUC0-t) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
- Nintedanib total absorption (AUC0-inf) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
- Nintedanib half-life in the blood (T1/2) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.